Terrance McGuire
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
TECX Reports Positive Phase 1 Data for TX2100 in HHT. Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
IVVD noted among health-care stocks moving on Monday. Invivyd (IVVD) was listed among twelve health-care stocks that showed price movement in Monday’s pre-market and intraday sessions, according to Benzinga. The mention reflects short-term trading activity but does not indicate a specific catalyst for the company.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Alector (ALEC) sees purchases by NVIDIA and Merck. Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.
Transaction History
| SEER | ▲ Buy | Grant | 16,500 | $0 | 7/28/2026 | View on chart |
| SEER | ▼ Sell | Other | 4,088 | — | 12/9/2025 | View on chart |
| SEER | ▲ Buy | Grant | 20,500 | $0 | 7/7/2025 | View on chart |
| TECX | ▼ Sell | Open Market | 500,000 | $8.6M | 4/7/2025 | View on chart |
| IVVD | ▼ Sell | Open Market | 103,474 | $46K | 12/31/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 86,545 | $42K | 12/30/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 83,744 | $44K | 12/27/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 83,817 | $46K | 12/26/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 68,161 | $35K | 12/24/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 75,776 | $34K | 12/23/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 119,805 | $51K | 12/20/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 152,067 | $66K | 12/19/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 74,764 | $35K | 12/18/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 97,410 | $47K | 12/17/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 65,359 | $31K | 12/16/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 125,000 | $73K | 12/12/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 160,400 | $95K | 12/11/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 175,000 | $103K | 12/10/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 150,000 | $92K | 12/9/2024 | View on chart |
| TECX | ▲ Buy | Grant | 1,073,062 | — | 6/20/2024 | View on chart |
| TECX | ▲ Buy | Grant | 20,262 | — | 6/20/2024 | View on chart |
| TECX | ▲ Buy | Grant | 64,652 | — | 6/20/2024 | View on chart |
| SEER | ▲ Buy | Grant | 58,178 | $0 | 6/12/2024 | View on chart |
| IVVD | ▼ Sell | Open Market | 112,381 | $187K | 5/29/2024 | View on chart |
| CYCN | ▲ Buy | Grant | 5,000 | $0 | 11/30/2023 | View on chart |
| ALEC | ▼ Sell | Open Market | 500,000 | $3.0M | 9/11/2023 | View on chart |
| ALEC | ▼ Sell | Other | 500,000 | $0 | 8/22/2023 | View on chart |
| ALEC | ▼ Sell | Other | 6,429 | $0 | 8/22/2023 | View on chart |
| ALEC | ▼ Sell | Other | 98,533 | $0 | 8/22/2023 | View on chart |
| ALEC | ▼ Sell | Other | 98,533 | $0 | 8/22/2023 | View on chart |
| ALEC | ▼ Sell | Other | 13,133 | $0 | 8/22/2023 | View on chart |
| CYCN | ▼ Sell | Open Market | 8 | $27 | 8/9/2023 | View on chart |
| SEER | ▲ Buy | Grant | 23,443 | $0 | 6/14/2023 | View on chart |
| ALEC | ▲ Buy | Grant | 26,250 | $0 | 6/14/2023 | View on chart |
| ALEC | ▼ Sell | Other | 13,133 | $0 | 11/16/2022 | View on chart |
| ALEC | ▼ Sell | Other | 500,000 | $0 | 11/16/2022 | View on chart |
| ALEC | ▼ Sell | Other | 6,429 | $0 | 11/16/2022 | View on chart |
| ALEC | ▼ Sell | Other | 98,533 | $0 | 11/16/2022 | View on chart |
| ALEC | ▼ Sell | Other | 98,533 | $0 | 11/16/2022 | View on chart |
| ALEC | ▲ Buy | Grant | 9,459 | $0 | 6/16/2022 | View on chart |
| SEER | ▲ Buy | Grant | 9,945 | $0 | 6/15/2022 | View on chart |
| ALEC | ▼ Sell | Other | 500,000 | $0 | 12/21/2021 | View on chart |
| ALEC | ▼ Sell | Other | 6,429 | $0 | 12/21/2021 | View on chart |
| ALEC | ▼ Sell | Other | 98,533 | $0 | 12/21/2021 | View on chart |
| ALEC | ▼ Sell | Other | 98,533 | $0 | 12/21/2021 | View on chart |
| ALEC | ▼ Sell | Other | 13,133 | $0 | 12/21/2021 | View on chart |
| CYCN | ▲ Buy | Open Market | 92,831 | $290K | 6/3/2021 | View on chart |
| CYCN | ▲ Buy | Open Market | 3,322 | $10K | 6/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced
Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced. Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.